Business Description
Medexus Pharmaceuticals Inc
NAICS : 325412
SIC : 3741
ISIN : CA70533E1088
Description
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.16 | |||||
Equity-to-Asset | 0.23 | |||||
Debt-to-Equity | 1.31 | |||||
Debt-to-EBITDA | 2.61 | |||||
Interest Coverage | 1.42 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 0.67 | |||||
Beneish M-Score | -3.38 | |||||
WACC vs ROIC |
Growth Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 1.1 | |||||
3-Year EPS without NRI Growth Rate | 58.5 | |||||
3-Year Book Growth Rate | 12.4 |
Momentum Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 76.02 | |||||
9-Day RSI | 70.2 | |||||
14-Day RSI | 67.32 | |||||
6-1 Month Momentum % | 45.83 | |||||
12-1 Month Momentum % | 11.87 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.01 | |||||
Quick Ratio | 0.41 | |||||
Cash Ratio | 0.11 | |||||
Days Inventory | 230.98 | |||||
Days Sales Outstanding | 66.13 | |||||
Days Payable | 232.12 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -8.5 | |||||
Shareholder Yield % | 39.71 |
Profitability Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 52.47 | |||||
Operating Margin % | 12.27 | |||||
Net Margin % | 2.22 | |||||
FCF Margin % | 18.55 | |||||
ROE % | 7.9 | |||||
ROA % | 1.5 | |||||
ROIC % | 17.65 | |||||
ROC (Joel Greenblatt) % | 70.52 | |||||
ROCE % | 12.47 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 22.73 | |||||
Forward PE Ratio | 14.52 | |||||
PE Ratio without NRI | 12.85 | |||||
Price-to-Owner-Earnings | 6 | |||||
PS Ratio | 0.56 | |||||
PB Ratio | 1.81 | |||||
Price-to-Free-Cash-Flow | 3.02 | |||||
Price-to-Operating-Cash-Flow | 2.64 | |||||
EV-to-EBIT | 9.17 | |||||
EV-to-EBITDA | 5.9 | |||||
EV-to-Forward-EBITDA | 3.13 | |||||
EV-to-Revenue | 0.92 | |||||
EV-to-Forward-Revenue | 1.02 | |||||
EV-to-FCF | 4.82 | |||||
Price-to-Projected-FCF | 1.2 | |||||
Price-to-Median-PS-Value | 0.51 | |||||
Earnings Yield (Greenblatt) % | 10.91 | |||||
FCF Yield % | 32.88 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Medexus Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil C$) | 141.986 | ||
EPS (TTM) (C$) | 0.143 | ||
Beta | 2.32 | ||
Volatility % | 86.19 | ||
14-Day RSI | 67.32 | ||
14-Day ATR (C$) | 0.169067 | ||
20-Day SMA (C$) | 2.8745 | ||
12-1 Month Momentum % | 11.87 | ||
52-Week Range (C$) | 1.47 - 3.27 | ||
Shares Outstanding (Mil) | 24.65 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Medexus Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Medexus Pharmaceuticals Inc Stock Events
Event | Date | Price(C$) | ||
---|---|---|---|---|
No Event Data |
Medexus Pharmaceuticals Inc Frequently Asked Questions
What is Medexus Pharmaceuticals Inc(TSX:MDP)'s stock price today?
When is next earnings date of Medexus Pharmaceuticals Inc(TSX:MDP)?
Does Medexus Pharmaceuticals Inc(TSX:MDP) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |